SLC5A2 and chronic kidney disease: Empagliflozin, a potent, selective inhibitor of sodium glucose cotransporter 2 (SGLT2), is an oral glucose-lowering agent widely used for the treatment of type 2 diabetes mellitus (DM) (13–15) (16), especially in patients with established cardiovascular disease (17) or heart failure or chronic kidney disease (CKD) (18) because of its favorable cardiorenal outcomes.